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• Tumor-infiltrating natural killer (NK) cells and CD8+ T cells are enriched with CD94/NKG2A and/or PD-1 in several cancer types, and HLA-E is overexpressed in several solid tumors 1 • Monalizumab (IPH2201) is a humanized immunoglobulin (IgG) 4 monoclonal antibody that targets NKG2A, blocking binding to its receptor HLA-E, which results in suppression of inhibitory signaling by tumors on NK cells and tumor-infiltrating CD8+ T cells 2 • Durvalumab is a human IgG1κ monoclonal antibody that blocks programmed death ligand-1 (PD-L1) binding to programmed death-1 (PD-1) and CD80 receptors, which enables T cells to recognize and kill tumor cells 3 • Blocking non-redundant NKG2A/HLA-E and PD-1/PD-L1 checkpoint pathways with the combination of monalizumab and durvalumab could enhance responses of NK and CD8+ T cells present in close proximity to tumor cells, thereby boosting innate and adaptive immunity (Figure 1 • Treatment continued until unacceptable toxicity, confirmed progressive disease, or withdrawal for another reason
Patients
• A total of 15 patients were enrolled in the dose escalation phase, and 40 MSS-CRC patients were enrolled in the dose expansion phase
• For the MSS-CRC expansion cohort:
-35 (87.5%) patients had ≥2 prior lines of therapy for recurrent/metastatic disease -32 (80.0%) patients discontinued treatment because of progressive disease -Median duration of follow-up was 6.6 months (0.3-14.0)
• Patient demographic and baseline disease characteristics of all enrolled patients are shown in Table 1 RESULTS • In this first-in-human study evaluating the combination of monalizumab plus durvalumab, the dose escalation phase showed a manageable toxicity profile, with no DLTs
• Preliminary efficacy data show encouraging activity in patients with heavily pretreated MSS-CRC
• The dose exploration phase in patients with CRC is ongoing
• Monalizumab is also being investigated in combination with cetuximab in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma (NCT02643550) 5 • In MSS-CRC expansion, there were 3 confirmed partial responses (PRs) and 11 patients with stable disease (SD), including 3 patients with tumor reduction who continued therapy for >200 days ( Table 3) • 8 patients (20%) had initial tumor reduction 
Conclusions

